_JIKK_2024-2.pdf_.png)
1.png){kind=logo}
.png)
.png)
.png)
.jpg)
Effectiveness And Safety Of Erdosteinie In Management Of Chronic Obstructive Pulmonary Disease (COPD): A Systematic And Meta-Analysis
Sari
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that cause limitation in the airflow and chronic inflammation. Erdosteine has been proposed as a potential therapeutic option for COPD management, based on its antioxidant activity and anti-inflammatory properties. The purpose of this systematic review and meta-analysis is to evaluate the effectiveness and safety of erdosteine in COPD patients. Multiple databases have been involved in the literature study following PRISMA guidelines, identifying randomized controlled trials (RCTs) that compared erdosteine with placebo. A total of seven studies were included in the qualitative analysis, and nine were analyzed quantitatively. Meta-analysis results indicated that erdosteine significantly improved forced expiratory volume in one second (FEV1), reduced reactive oxygen species (ROS) and 8-isoprostan levels, and lowered interleukin-8 (IL-8) concentrations. Subgroup analyses demonstrated greater benefits in patients with moderate to severe COPD (stage II/III). Safety analysis revealed that erdosteine was generally well-tolerated, with only mild adverse effects reported. However, study limitations included high heterogeneity and potential bias in some trials. Overall, the findings suggest that erdosteine is an effective and safe adjunct therapy for COPD.
Kata Kunci
Teks Lengkap:
PDFReferensi
Adeloye, D., Song, P., Zhu, Y., Campbell, H., Sheikh, A., & Rudan, I. (2022). Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. The Lancet Respiratory Medicine, 10(5), 447-458. https://doi.org/10.1016/S2213-2600(21)00511-7
Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., de Oca, M. M., Mortimer, K., Papi, A., Pavord, I., Roche, N., Salvi, S., Sin, D. D., Singh, D., Stockley, R., Varela, M. V. L., Wedzicha, J. A., … Vogelmeier, C. F. (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Respirology (Carlton, Vic.), 28(4), 316–338. https://doi.org/10.1111/resp.14486
Budiono, E., Ratnasari, N., & Tjandra, L (2019). Effects of erdosteine administration in serum C-reactive protein level in stable chronic obstructive pulmonary disease patients. Acta Interna: Journal of Internal Medicine. 7(1), 1–9. https://doi.org/10.22146/actainterna.48439
Calverley, P. M. A., Papi, A., Page, C., Rogliani, P., Dal Negro, R. W., Cazzola, M., Cicero, A. F., & Wedzicha, J. A. (2022). The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset. International journal of chronic obstructive pulmonary disease, 17, 1909–1920. https://doi.org/10.2147/COPD.S369804
Cazzola, M., Calzetta, L., Page, C., Rogliani, P., & Matera, M. G. (2018). Impact of erdosteine on chronic bronchitis and COPD: a meta-analysis. Pulmonary pharmacology & therapeutics, 48, 185-194. https://doi.org/10.1016/j.pupt.2017.11.009
Cazzola, M., Floriani, I., & Page, C. P. (2010). The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulmonary pharmacology & therapeutics, 23(2), 135–144. https://doi.org/10.1016/j.pupt.2009.10.002
Dal Negro, R. W., Visconti, M., Micheletto, C., & Tognella, S. (2008). Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulmonary pharmacology & therapeutics, 21(2), 304–308. https://doi.org/10.1016/j.pupt.2007.07.004
Dal Negro, R. W., Visconti, M., & Turco, P. (2015). Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial. Pulmonary pharmacology & therapeutics, 33, 47–51. https://doi.org/10.1016/j.pupt.2015.06.004
Dal Negro, R. W., & Visconti, M. (2016). Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial. Pulmonary pharmacology & therapeutics, 41, 48–51. https://doi.org/10.1016/j.pupt.2016.09.007
Dal Negro, R. W., Wedzicha, J. A., Iversen, M., Fontana, G., Page, C., Cicero, A. F., ... & McGarvey, L. (2017). Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal, 50(4) 1700711.
https://doi.org/10.1183/13993003.00711-2017
Global Initiative for Chronic Obstructive Lung Disease. (2023). Global Initiative for Chronic Obstructive Lung Disease (2023 Report). https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf
Halpin, D. M. G., Celli, B. R., Criner, G. J., Frith, P., López Varela, M. V., Salvi, S., Vogelmeier, C. F., Chen, R., Mortimer, K., Montes de Oca, M., Aisanov, Z., Obaseki, D., Decker, R., & Agusti, A. (2019). The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 23(11), 1131–1141. https://doi.org/10.5588/ijtld.19.0397
Hillas, G., Nikolakopoulou, S., Hussain, S., & Vassilakopoulos, T. (2013). Antioxidants and mucolytics in COPD management: when (if ever) and in whom?. Current drug targets, 14(2), 225–234. https://doi.org/10.2174/1389450111314020007
Kuzhko, M., Borysov, D., Tseluiko, T., & Antonyuk, V. (2020). Efficacy of erdosteine in complex treatment of patients with COPD. Asthma & Allergy. 1, 37–42. https://doi.org/10.31655/2307-3373-2020-1-37-42
Moretti, M., Bottrighi, P., Dallari, R., Da Porto, R., Dolcetti, A., Grandi, P., ... & Potena, A. (2004). The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs under experimental and clinical research, 30(4), 143-152.
Moretti, M., & Fagnani, S. (2015). Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD. International journal of chronic obstructive pulmonary disease, 10, 2319–2325. https://doi.org/10.2147/COPD.S87091
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C.,
Devereaux, P. J., Altman, D. G. (2010). CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c869. https://doi.org/10.1136/bmj.c869
O'Reilly S. (2016). Chronic Obstructive Pulmonary Disease. American journal of lifestyle medicine, 11(4), 296–302. https://doi.org/10.1177/1559827616656593
Papi, A., Avdeev, S., Calverley, P. M. A., Cordeiro, C. R., Jesenak, M., Koblížek, V., Petkova, D., Rogliani, P., Tarraf, H., Tzanakis, N., Ulmeanu, R., Uzaslan, E., & Adir, Y. (2020). Use of mucolytics in COPD: A Delphi consensus study. Respiratory medicine, 175, 106190. https://doi.org/10.1016/j.rmed.2020.106190
Puspitasari, Y., & Suradi, R. (2015). Pengaruh Erdostein pada Kadar Glutathione, Interleukin 8, Volume Ekspirasi Paksa Detik Pertama, dan Skor CAT pada Penyakit Paru Obstruktif Kronik Stabil. Jurnal Respirologi Indonesia. 35(3), 181-192.
Rogliani, P., Matera, M. G., Page, C., Puxeddu, E., Cazzola, M., & Calzetta, L. (2019). Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respiratory research, 20(1), 104.
https://doi.org/10.1186/s12931-019-1078-y
Vora, A., Tiwaskar, M., Prajapati, C., Jose, A., Qamra, A., & Muralidharan, P. (2025). Erdosteine: Reigniting a Thiol Mucolytic for Management of Chronic Obstructive Pulmonary Disease. The Journal of the Association of Physicians of India, 73(1), 29–34. https://doi.org/10.59556/japi.73.0810
DOI: https://doi.org/10.33024/jikk.v12i9.20524
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc4.footer##
Pendidikan Dokter Universitas Malahayati Lampung
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.